13F Holdings
中文EN

PHAT Phathom Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1783183 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY86.8%
TTM net income YoY69.8%
TTM EPS YoY73.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin80.7%
Operating margin-9.3%
Net margin-30.2%
FCF margin-7.7%
EBITDA margin-9.1%

Returns

ROE—
ROA-28.4%
ROIC (approx.)—
Asset turnover0.94x

Leverage & solvency

Liabilities / assets200.8%
Debt / equity—
Current ratio1.76x
Interest coverage-0.41x

Cash quality & payout

Operating cash flow / net income0.25x
Accruals ratio-21.3%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$175.11M$55.25M$682,000$0—
Cost of revenue$22.60M$7.97M$167,000$0—
Gross profit$152.51M$47.28M$515,000$0—
R&D expense$32.78M$34.08M$49.90M$71.44M$72.34M
SG&A expense$279.72M$290.66M$117.93M$101.00M$62.74M
Operating income-$159.99M-$277.47M-$167.31M-$172.44M-$135.08M
Interest expense$68.11M$72.01M$41.97M$27.30M$6.79M
Pretax income-$221.25M-$334.33M———
Income tax$0$0$0$0$0
Net income-$221.25M-$334.33M-$201.59M-$197.72M-$143.88M
EBITDA-$159.35M-$276.67M-$166.74M-$171.82M-$134.56M
EPS (basic)-3.03-5.29-3.93-5.05-3.89
EPS (diluted)-3.03-5.29-3.93-5.05-3.89
Weighted avg. shares (diluted)72.92M63.18M51.29M39.12M37.00M
Balance sheet
Cash & equivalents$129.97M$297.26M$381.39M$155.38M$183.26M
Receivables$78.13M$38.80M$1.64M$0—
Inventory$5.52M$3.21M$1.21M$0—
Current assets$228.97M$360.13M$397.43M$160.51M$186.53M
PP&E, net$1.06M$1.48M$2.15M$1.21M$650,000
Total assets$259.15M$378.32M$413.84M$164.81M$189.43M
Current liabilities$132.04M$85.73M$38.78M$26.24M$18.92M
Short-term debt$0$0$0$0—
Long-term debt$209.09M$201.41M$137.84M$95.26M$89.67M
Total debt$209.09M$201.41M$137.84M$95.26M$89.67M
Total liabilities$697.32M$631.90M$486.60M$239.62M$117.28M
Shareholders' equity-$438.17M-$253.58M-$72.76M-$74.81M$72.16M
Net debt$79.11M-$95.85M-$243.55M-$60.12M-$93.59M
Shares outstanding71.42M68.52M57.97M41.47M30.51M
Cash flow statement
Operating cash flow-$166.78M-$266.77M-$137.58M-$146.53M-$148.46M
Capital expenditure$229,000$135,000$1.63M$1.04M$328,000
Free cash flow-$167.00M-$266.90M-$139.21M-$147.57M-$148.78M
Investing cash flow-$229,000-$135,000-$1.63M-$1.04M-$328,000
Financing cash flow-$288,000$182.77M$367.58M$120.04M$44.71M
Depreciation & amortization$633,000$795,000$575,000$620,000$521,000
Stock-based compensation$28.72M$24.05M$45.02M$24.13M$16.81M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.